Alkermes (ALKS) Stock
Mid cap biotech developing brain and addiction treatments. Here's the price, business snapshot, and what's worth knowing about Alkermes in July 2026.
Alkermes plc (ALKS) is a biopharmaceutical company focused on developing medicines for people living with serious neuropsychiatric, neurologic and addiction disorders. The company combines proprietary formulation and delivery technologies with a pipeline that includes marketed products and earlier-stage candidates. Its revenues come from product sales, royalties and partner collaborations, while research and development is a major cost driver. Investors should be aware that Alkermes is R&D‑intensive and sensitive to clinical trial results, regulatory approvals and reimbursement decisions — outcomes that can materially affect valuation. With a market capitalisation around $5.2bn, Alkermes occupies a mid-cap position in the biotechnology sector, offering exposure to neuroscience therapeutics but also carrying typical sector volatility. This summary is educational only and not personal financial advice; prospective investors should review the company’s latest filings and consider their own risk tolerance.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alkermes stock, expecting its price to rise significantly in the future.
Financial Health
Alkermes is performing well with strong revenue and profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ALKS
UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Published: 2 December 2025
Explore BasketInjectable Drug Revolution: What's Next Beyond Pills?
The UK's approval of GSK's long-acting HIV drug marks a pivotal shift from daily pills to less frequent injections. This theme focuses on the pharmaceutical innovators leading the charge in developing and commercializing long-acting therapeutic technologies.
Published: 17 October 2025
Explore BasketEarly Alzheimer's Detection: Could Blood Tests Replace Scans?
The FDA's approval of Roche and Eli Lilly's blood test marks a pivotal shift toward early and accessible Alzheimer's diagnosis in primary care. This breakthrough is expected to accelerate growth for companies in the diagnostics sector and expand the market for new Alzheimer's treatments.
Published: 14 October 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: 11 July 2025
Explore BasketThe Atlantic Shift: Pharma's US Listing Trend
AstraZeneca's potential move to US markets signals a growing trend among international pharmaceutical companies seeking higher valuations. This collection features global biopharma giants that could benefit from similar strategies or favorable US market dynamics.
Published: 2 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical and regulatory milestones can move the share price; watch study readouts and approvals, though outcomes are uncertain.
R&D Intensity
High R&D spending supports innovation but increases cash-burn risk; funding and trial success are important to monitor.
Commercial & Partnerships
Revenue is a mix of product sales, royalties and collaborations; commercial uptake and payer decisions influence growth, and competition remains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
